Arch Biopartners Doses First Patient in Canada for...
Category : Clinical Trial Update 14 November 2024Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac...
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac...
Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial...
US FDA grants breakthrough therapy designation to Johnson & Johnson’s nipocalimab to treat...
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to t...
Overview EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best...